Cameron Turtle
Associate Professor
Medicine
Fred Hutchinson Cancer Rearch Center
United States of America
Biography
Dr. Turtle is a hematology oncologist who specializes in treating blood diseases with bone marrow transplantation. Dr. Turtle is an acting instructor at the University of Washington and a research associate at Fred Hutchinson Cancer Research Center. Degrees Ph.D., University of Queensland, Australia, 2005. M.B.B.S. (Medicine), University of Sydney, Australia, 1993
Research Interest
Dr. Turtle’s laboratory in the FHCRC Clinical Research Division, Program in Immunology is focused on understanding the characteristics of distinct subsets of human T cell, their potential utility for tumor immunotherapy and their role in immune reconstitution after hematopoietic stem cell transplantation (HCT).
Publications
-
Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL et al.. 2016. CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.. Oncoimmunology. 5(6):e1168555.
-
Gardner R, Wu D, Cherian S, Fang M, Hanafi L-A, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG et al.. 2016. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.. Blood. 127(20):2406-2410.
-
Turtle CJ, Riddell SR, Maloney DG. 2016. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.. Clinical pharmacology and therapeutics. 100(3):252-8.
-
Turtle CJ, Hay KA, Hanafi L-A, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S et al.. 2017. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(26):3010-3020
